Literature DB >> 17621815

Septectomy and septal dermoplasty for the treatment of severe transfusion-dependent epistaxis in patients with hereditary hemorrhagic telangiectasia and septal perforation.

Gregory T Lesnik1, Douglas A Ross, Katharine J Henderson, John K Joe, Steven B Leder, Robert I White.   

Abstract

BACKGROUND: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder characterized by abnormal angiogenesis with resultant telangiectasia formation in mucocutaneous tissues, visceral organs, and the central nervous system. The most common manifestation of HHT is epistaxis resulting from trauma to thin-walled telangiectasias. Many patients with HHT experience worsened epistaxis due to the presence of a septal perforation. Septal perforation in HHT patients results from aggressive noncartilage sparing treatments such as monopolar cauterization. Although the mainstay of treatment for patients with severe transfusion-dependent HHT remains to be septal dermoplasty (SD), patients with a septal perforation are less likely to have a successful outcome. In this small subset of patients, septectomy (ST) combined with SD is proposed to eliminate this variable to improve skin graft uptake and therefore outcome. This study reviews the indications, procedure, and outcome of nine patients with severe transfusion-dependent HHT and septal perforation who underwent the combined procedure of SD/ST.
METHODS: Nine HHT patients with severe transfusion-dependent epistaxis and septal perforation underwent SD/ST at our institution over a 5-year period. Quality of life, including number of daily events of epistaxis, and transfusion requirements were determined before and after surgery. Technical aspects of the procedure as well as complications were reviewed.
RESULTS: The combined procedure of SD/ST resulted in a long-lasting subjective improvement in quality of life for all patients. Similarly, transfusion requirements were reduced from 22.61 to 9.57 (p < 0.05). There were no complications or increased morbidity from the procedure.
CONCLUSION: Combined SD/ST is a safe and effective treatment for HHT patients with transfusion-dependent epistaxis and septal perforation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621815     DOI: 10.2500/ajr.2007.21.3017

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  7 in total

Review 1.  Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.

Authors:  Arash Abiri; Khodayar Goshtasbi; Marlon Maducdoc; Ronald Sahyouni; Marilene B Wang; Edward C Kuan
Journal:  Lasers Surg Med       Date:  2019-08-22       Impact factor: 4.025

2.  Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia.

Authors:  Sung Ok Park; Mamta Wankhede; Young Jae Lee; Eun-Jung Choi; Naime Fliess; Se-Woon Choe; Seh-Hoon Oh; Glenn Walter; Mohan K Raizada; Brian S Sorg; S Paul Oh
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

3.  Nasal surgery in patients with systemic disorders.

Authors:  Florian Sachse; Wolfgang Stoll
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2011-04-27

Review 4.  Epistaxis in hereditary hemorrhagic telangiectasia: an evidence based review of surgical management.

Authors:  Christopher J Chin; Brian W Rotenberg; Ian J Witterick
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-01-12

5.  Endoscopic surgical treatment of epistaxis in hereditary haemorrhagic telangiectasia: our experience.

Authors:  Fabio Pagella; Alessandro Pusateri; Eugenia Maiorano; Giuseppe Spinozzi; Sara Ugolini; Roberta Lizzio; Rosolino Mirabella; Carmine Tinelli; Carla Olivieri; Elina Matti
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-02       Impact factor: 2.124

Review 6.  Pericytes as targets in hereditary hemorrhagic telangiectasia.

Authors:  Jérémy Thalgott; Damien Dos-Santos-Luis; Franck Lebrin
Journal:  Front Genet       Date:  2015-02-13       Impact factor: 4.599

7.  Long-term efficacy assessment of current treatment options for epistaxis in HHT.

Authors:  Cilgia Dür; L Anschuetz; S Negoias; O C Bulut; A Angelillo-Scherrer; M Caversaccio
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-03-04       Impact factor: 2.503

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.